{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:38:08Z","timestamp":1792269488825,"version":"4.4.0"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The risk of severe myelosuppression following regional arterial perfusion chemotherapy in heavily pre-treated patients is often underestimated, especially when pre-treatment hematologic status appears adequate. This case highlights the unexpectedly profound bone marrow toxicity that can occur under these circumstances and details the critical management strategies required.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>\n                      We report a case of a 51-year-old female patient with advanced triple negative breast cancer (TNBC) who developed severe myelosuppression following regional arterial perfusion chemotherapy, despite the chemotherapy dose being lower than the standard systemic dose. The patient had grade I myelosuppression before regional arterial perfusion chemotherapy; however, after perfusion with albumin paclitaxel and gemcitabine, she developed life-threatening severe myelosuppression, with absolute neutrophil count (ANC) dropping to 0 and remaining \u22640.01\u00d710\n                      <jats:sup>9<\/jats:sup>\n                      \/L for 3 consecutive days. Timely administration of granulocyte colony-stimulating factor (G-CSF), antibiotics, and supportive care effectively reversed the myelosuppression and prevented infection. Due to chest tightness and dyspnea caused by the massive pleural effusion, thoracentesis drainage was decisively performed when the white blood cell count showed an upward trend (neutrophil count, 0.06\u00d710\n                      <jats:sup>9<\/jats:sup>\n                      \/L). The procedure was smooth and without complications.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case underscores that locoregional chemotherapy, even at reduced doses, can cause profound myelosuppression in extensively pre-treated patients. It also illustrates that a pre-treatment ANC within the normal range may not reliably reflect bone marrow reserve in this population. Prompt, intensive supportive care\u2014including prophylactic antibiotics, G-CSF, and protective isolation\u2014is essential. In carefully selected patients during early hematologic recovery, under strict infection prevention measures and multidisciplinary evaluation, invasive procedures such as thoracentesis may be feasible.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1872193","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T04:34:35Z","timestamp":1789101275000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Life-threatening neutropenia with absolute neutrophil count of zero after low-dose regional arterial infusion chemotherapy to lung in a patient with advanced triple-negative breast cancer after multiple lines of treatment"],"prefix":"10.3389","volume":"16","author":[{"given":"Yiran","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Gastrointestinal Oncology, Shanghai Gobroad Cancer Hospital","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianlin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Oncology, Shanghai Gobroad Cancer Hospital","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjun","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Oncology, Shanghai Gobroad Cancer Hospital","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Oncology, Shanghai Gobroad Cancer Hospital","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-024-00714-6","article-title":"Towards targeting the breast cancer immune microenvironment","volume":"24","author":"Michael","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2511734","article-title":"Sacituzumab Govitecan in untreated, advanced triple-negative breast cancer","volume":"393","author":"Javier","year":"2025","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2026.1764945","article-title":"Comparative efficacy and safety of individual short-acting versus long-acting granulocyte colony-stimulating factors, including biosimilars, for primary prophylaxis of chemotherapy-induced myelosuppression in breast cancer patients: a systematic review and network meta-analysis protocol","volume":"16","author":"Xiaoyun","year":"2026","journal-title":"Front Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16213711","article-title":"Enhancing anti-PD-1 immunotherapy by targeting MDSCs via hepatic arterial infusion in breast cancer liver metastases","volume":"16","author":"Kim","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2026.1794578","article-title":"Comparative study of triple intravenous chemotherapy versus dual chemotherapy combined with hepatic arterial infusion in patients with liver metastases from colorectal cancer","volume":"16","author":"Zhou","year":"2026","journal-title":"Front Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2026.1778951","article-title":"Development and validation of a machine learning-based predictive model for chemotherapy-induced myelosuppression in colorectal cancer patients","volume":"13","author":"Xue","year":"2026","journal-title":"Front Med (Lausanne)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2026.1754502","article-title":"Trilaciclib for prophylaxis of chemotherapy-induced myelosuppression in solid tumor patients: a systematic review and meta-analysis","volume":"17","author":"Ting","year":"2026","journal-title":"Front Pharmacol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2013.1234","article-title":"Risk factors for hematological toxicity of chemotherapy for bone and soft tissue sarcoma","volume":"5","author":"Zhengxiao","year":"2013","journal-title":"Oncol Lett"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1544061","article-title":"Advances in hepatic arterial perfusion chemotherapy for hepatic metastases","volume":"15","author":"Haodi","year":"2025","journal-title":"Front Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2024.03.016","article-title":"Double-balloon catheter-mediated transarterial chemotherapy delivery in a swine model: a mechanism recruiting the vasa vasorum for localized therapies","volume":"35","author":"Khashayar","year":"2024","journal-title":"J Vasc Interv Radiol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15061664","article-title":"Anatomical targeting of anticancer drugs to solid tumors using specific administration routes: review","volume":"15","author":"Akira","year":"2023","journal-title":"Pharmaceutics"},{"key":"B12","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s44178-026-00234-3","article-title":"CACA guidelines for managing cancer therapy-induced neutropenia (2026)","volume":"5","author":"Xiao","year":"2026","journal-title":"Holistic Integr Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102427","article-title":"Chemotherapy-induced neutropenia and emerging agents for prevention and treatment: a review","volume":"109","author":"Blayney","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/hematolrep18010014","article-title":"Factors influencing the use of G-CSF in drug-induced agranulocytosis","volume":"18","author":"Emmanuel","year":"2026","journal-title":"Hematol Rep"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-024-10163-z","article-title":"Critically ill patients will benefit from single isolated laminar-air-flow wards by improving the environmental microbial composition","volume":"24","author":"Tianji","year":"2024","journal-title":"BMC Infect Dis"},{"key":"B16","article-title":"Empirical and targeted antimicrobial therapy in patients with febrile neutropenia and haematological Malignancy or after haematopoietic cell transplantation: recommendations from the 10th European Conference on Infections in Leukaemia","volume-title":"The Lancet Infectious Diseases","author":"Averbuch","year":"2025"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-1219903\/v1","article-title":"Maximum daily dose of G-CSF is critical for preventing recurrence of febrile neutropenia in patients with gynecologic cancer: a case-control study","volume":"101","author":"Nam Kyeong","year":"2022","journal-title":"Med (Baltimore)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1641747","article-title":"Drug-induced agranulocytosis: a disproportionality analysis and umbrella review","volume":"16","author":"Lu","year":"2025","journal-title":"Front Pharmacol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"32875292","DOI":"10.1177\/17588359261430556","article-title":"Effectiveness, safety, and biomarker analysis of sacituzumab govitecan in Chinese metastatic breast cancer: a multicenter real-world study","volume":"18","author":"Li","year":"2026","journal-title":"Ther Adv Med Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s00262-025-04085-1","article-title":"Efficacy and safety of local-regional therapy combined with chemotherapy, immune checkpoint inhibitors and lenvatinib as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter retrospective cohort study","volume":"74","author":"Li","year":"2025","journal-title":"Cancer Immunol Immunother"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1872193\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T04:35:09Z","timestamp":1789101309000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1872193\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":20,"alternative-id":["10.3389\/fonc.2026.1872193"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1872193","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]},"article-number":"1872193"}}